Poland· PL-100510229
Vyepti
A eptinezumab product containing eptinezumabum, registered in Poland by H. Lundbeck A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Eptinezumab is registered in 14 of 19 countries.
Countries holding a registration under ATC N02CD05 (eptinezumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Eptinezumab · ATC N02CD05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Eptinezumabum
- Manufacturer
- H. Lundbeck A/S
- Country
- Poland (PL)
- ATC code
- N02CD05
- ATC class
- Eptinezumab
- Defined daily dose
- 1.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Eptinezumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVYEPTIAbacus Medicine A/S
- CzechiaVYEPTIH. Lundbeck A/S, Valby
- United StatesVyeptiLundbeck Pharmaceuticals LLC
- SpainVYEPTI 100 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONH. Lundbeck A/S
- BelgiumVyepti 100 mgH. Lundbeck
- CanadaVYEPTILUNDBECK CANADA INC
- SwitzerlandVyepti 100 mg/1 ml, Konzentrat zur Herstellung einer InfusionslösungLundbeck (Schweiz) AG
- NetherlandsVyepti 100 mg/ml, concentraat voor oplossing voor infusieH. Lundbeck A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vyepti
- Norway · Vyepti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f457c48a-647c-43c5-99fb-8434315ccdf7 GET /v1/drugs/f457c48a-647c-43c5-99fb-8434315ccdf7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "300 mg/ml",
"packaging": "Rpz ¦ EU/1/21/1599/003 ¦ 159543\n1 fiol. 3 ml",
"substance": "Eptinezumabum 300 mg/ml",
"common_name": "Eptinezumabum",
"pl_product_id": "100510229",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about eptinezumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.